ArticlePhytochemical analysis : PCA2026
Antifibrotic Effects of Yi-Qi-Jian-Pi-Xiao-Yu Formula in Kidney via HIF1A-Driven M1 Macrophage Polarization.
Article in Phytochemical analysis : PCA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundA traditional Chinese medicine Yi-Qi-Jian-Pi-Xiao-Yu (YQJPXY) formula can potentially ameliorate chronic kidney disease (CKD), but its effect on renal fibrosis (RF), a prevalent pathological feature of CKD, remains unclear.
methodsTo mimic renal injury and fibrosis, a mouse unilateral ureteral obstruction (UUO) model was employed. Using hematoxylin-eosin and Masson's trichrome stains, enzyme-linked immunosorbent assay, and immunofluorescence, the effects of YQJPXY on renal injury in UUO mice were evaluated. A series of bioinformatics analyses were then conducted to explore the key genes and immune cells involved in the therapeutic mechanism of YQJPXY. Finally, in vivo and in vitro studies provided multifaceted evaluations of YQJPXY against RF from the perspectives of macrophage dynamics and roles of HIF1A.
resultsYQJPXY treatment significantly reduced levels of TGF-β1 and IL-6, attenuated tubular damage, decreased extracellular matrix protein (FN and Col-I) expressions, and modulated fibrosis and epithelial-mesenchymal transition markers in UUO mice in a dose-dependent manner. Bioinformatics analysis identified HIF1A as the key target of YQJPXY against RF. In vivo, HIF1A deficiency lessened RF and recruitment of CD45
conclusionYQJPXY alleviates RF by attenuating HIF1A-mediated M1 macrophage polarization, providing a potential therapeutic approach for CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.